注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
PMV Pharmaceuticals Inc是一家致力於發現和開發靶向p53的小分子以及腫瘤未知療法的精密腫瘤學公司。該公司的主要候選產品PC14586是一種旨在有效和選擇性地糾正由特定p53突變Y220C引起的p53錯誤折疊,同時保留野生型p53的口服小分子。PC14586旨在通過佔據氨基酸位置220的酪氨酸至半胱氨酸突變產生的縫隙來恢復野生型構象。該公司還利用其精準腫瘤學平台開發了一種口服小分子候選產品,這種候選產品在結構上糾正其他p53熱點突變以恢復其野生型功能,並針對某些野生型p53功能沉默的癌症。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Scott W. Lowe | - | - | Chairman of Scientific Advisory Board |
David H. Mack | 62 | 2013 | Co-Founder, CEO, President & Director |
Arnold J. Levine | 84 | 2013 | Co-Founder, Director & Member of Scientific Advisory Board |
Frank P. McCormick | 74 | - | Member of Scientific Advisory Board |
Karen H. Vousden | 65 | - | Member of Scientific Advisory Board |
Charles M. Baum | 66 | 2021 | Independent Director |
Michael E. Jung | - | - | Member of Scientific Advisory Board |
Richard A. Heyman | 67 | 2020 | Independent Chairman of the Board of Directors & Member of Scientific Advisory Board |
Charles L. Sawyers | 65 | - | Member of scientific Advisory Board |
Kirsten Flowers | 49 | 2022 | Independent Director |
Carol G. Gallagher | 59 | 2022 | Independent Director |
Guillermina Lozano | - | 2021 | Member of Scientific Advisory Board |
Laurie D. Stelzer | 56 | 2020 | Independent Director |
Thomas E. Shenk | 77 | 2013 | Co-Founder & Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核